SAN FRANCISCO — ­To one side, it’s a story of betrayal and double dealing. To the other, it’s an example of overreaching by a drug company seeking to knock out a competitor.

On Oct. 17, Medivation Inc. and UCLA chemistry professor Michael Jung will face off in San Francisco Superior Court in a trial to determine whether Jung lived up to his end of a 2005 research agreement that led to the development of the new prostate cancer drug, Xtandi.